Search
Mira Pharmaceuticals Inc
MIRAAdd to Watchlist
0.945USD
-0.003-0.26%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
39.70MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.26%
5 Days
-6.46%
1 Month
-10.87%
6 Months
-36.59%
Year to Date
-37.43%
1 Year
-21.27%
Key Figures
0.927Open
0.950High
44.93KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.11%Turnover Ratio
0.947Prev. Close
0.920Low
31.72KTurnover
LossP/E Static
4.25P/B
0.00%Div Yield TTM
-180.57%ROA
2.45052wk High
0.91Volume Ratio
-7.85MNet Profit
42.02MShares
-1.2708EPS TTM
--Beta
-589.41%ROE
0.73052wk Low
3.17%Amplitude
--Gross Margin
39.70MMarket Cap
-2.38Reward/Risk
4.46%Risk Rate
TradingKey Stock Score of Mira Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Mira Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 248 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mira Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Mira Pharmaceuticals Inc Highlights
StrengthsRisks
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.74, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.36M shares, increasing 26.28% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
3.000
Target Price
+109.79%
Upside Space
Mira Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mira Pharmaceuticals Inc Info
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Ticker SymbolMIRA
CompanyMira Pharmaceuticals Inc
CEOAminov (Erez)
Websitehttps://mirapharmaceuticals.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Mira Pharmaceuticals Inc (MIRA)?
The current price of Mira Pharmaceuticals Inc (MIRA) is 0.94.
What is the symbol of Mira Pharmaceuticals Inc?
The ticker symbol of Mira Pharmaceuticals Inc is MIRA.
What is the 52-week high of Mira Pharmaceuticals Inc?
The 52-week high of Mira Pharmaceuticals Inc is 2.45.
What is the 52-week low of Mira Pharmaceuticals Inc?
The 52-week low of Mira Pharmaceuticals Inc is 0.73.
What is the market capitalization of Mira Pharmaceuticals Inc?
The market capitalization of Mira Pharmaceuticals Inc is 39.70M.
What is the Earnings Per Share (EPS TTM) of Mira Pharmaceuticals Inc (MIRA)?
The Earnings Per Share (EPS TTM) of Mira Pharmaceuticals Inc (MIRA) is -1.35.